Search

6035 Background: Cisplatin based chemoradiotherapy (CRT) is the standard treatment for advanced head and neck cancer (HNC), currently the recommended doses are 30-40 mg/m2 every week or 80-100mg/m2...

e22133 Background: EGFR mutation in NSCLC is a biomarker of tumor response to EGFR-TKI. However, lacking in sufficient tumor tissue has limitation to acquire EGFR mutation status in clinical practice. Previous studies showed that lower SUV was associated with better TKI treatment. The objective of this study was to predict EGFR mutation status of NSCLC patients based on a model consisting of 18F-fluorodeoxyglucose (FDG) uptake and supported by primary tumor size and smoking history. Methods: We retrospectively reviewed NSCLC patients undergoing EGFR mutation test and pretreatment PET/CT between March 2009 and December 2013. The relationship of EGFR mutations with both SUV uptake value of primary tumors and patient characteristics were evaluated, and a multivariate logistic regression analysis was constructed. The model was assessed by area under the receiver operating characteristic curve (AUC) and was prospectively validated during January to June 2014. Results: 316 patients meeting criteria were enrolle...

e19060 Background: NSCLC accounts for 85%-90%of lung cancers, in which brain metastases (BMs) occur in 20–40%of all NSCLC cases. WBRT is the standard treatment for BMs in NSCLC, which leads to a un...

6036 Background: The cisplatin (CDDP)-based CT is considered as the standard regimen for the treatment of moderate to advanced SCCHN. Recently, an alteration is made to carboplatin (CBDCA) because ...

e19121 Background: Epidermal growth factor receptor (EGFR) mutation status is one of the most critical factors for clinicians to develop multiple strategies in non-small cell lung cancer (NSCLC) pa...

e22254 Background: Copper metabolism MURR1 domain-containing10(COMMD10), a novel component of FCOMMD protein family, is a protein involved in multiple cellular pathways, including copper homeostasis, NF-κB and HIF signalling. However, its expression and role in HBV-related hepatocellular carcinoma remain unclear. Methods: The expression of COMMD10 was detected in clinical formalin-fixed paraffin-embedded (FFPE) hepatocellular carcinoma tissues by immunohistochemistry with clinicopathological analyses and determined in matched pairs of fresh frozen tissues by Quantitative Real time PCR or Western blot. Results: Immunohistochemistry staining was performed in 129 cases of clinical paraffin-embedded HCC tissues. The staining signal of COMMD10 was mainly observed in adjacent normal livers or cirrhotic livers. Meanwhile,no signals or only weak signals were detected in HCC tissues. Among 129 samples, 94 cases of them (72.9%) exhibited low-expression of COMMD10 (0 to 1+) and high-expression of COMMD10 (2+ to 3+) ...

4157 Background: Primary results of POF as 1st-line treatment for AGC have been presented at ASCO 2008. The purpose of this study was to assess the efficacy and toxicity of POF in primary refractor...

e15642 Background: Primary results of POF as 1st and 2nd line treatment for AGC have been presented at ASCO 2007 and 2008. We report here data on the feasibility and the toxicity of POF versus IF(Dank, et al, ASCO 2005) in 1st line treatment of AGC. Methods: Patients with previously untreated, advanced, unresectable, and histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction were randomly assigned to POF or IF regiment. Treatment was continued until disease progressed, unacceptable toxicity, or patient choice. Results: 25 patients were entered in this study between March 2007 and July 2007: 13 in the POF group and 12 in the IF group. The median patient age was 55 years (range, 36 to 67 years), 18 were males and 7 were females. No complete response was observed. The response rate was 62.5% (POF) and 33.3% (IF) respectively. At a median follow-up of 285 days, 7(POF) versus 6(IF) patients were still alive. Hematological toxicity was the most frequent toxicity in both groups. Grade 3 to 4 neutropenia were 38.5% (POF) versus 8.3% (IF). Diarrhea was found 0% and 8.3% in POF and IF group respectively. No grade 3 peripheral neurotoxicity was observed. Conclusions: Compared with IF regiment, POF could also be used as first-line treatment for AGC with acceptable safety profile, good efficacy, and more encouraging results. No significant financial relationships to disclose.